Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Multiple myeloma (MM) consists of several distinct cytogenetic subtypes, and we hypothesized that each subtype may have a unique mode of initial presentation and end-organ damage. We studied 484 patients with newly diagnosed MM to determine the relationship between specific myeloma-defining event (MDE) and the cytogenetic subtype. Patients were divided into four non-overlapping groups based on the MDE at diagnosis: isolated renal failure, isolated anemia, isolated lytic bone disease or a combination (mixed). MM with translocations without trisomies accounted for 30% of all patients, but accounted for 50% of patients with renal failure. Specifically, the t(14;16) translocation accounted for only 5% of all MM patients, but was present in 13.5% of patients with renal failure as MDE. Among patients with t(14;16), 25% presented with renal failure only as MDE. Patients with isolated renal failure as MDE had significantly poorer survival compared with all other groups, whereas patients with bone disease as MDE had the best outcome (P<0.001). Our findings support the hypothesis that in addition to prognostic differences, there is significant heterogeneity in clinical presentation associated with the cytogenetic subtype, suggesting that MM encompasses a group of cytogenetically and phenotypically distinct disorders rather than a single entity.

Original languageEnglish (US)
Pages (from-to)398-403
Number of pages6
JournalLeukemia
Volume28
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Cytogenetics
Multiple Myeloma
Renal Insufficiency
Bone Diseases
Trisomy
Anemia
Survival

Keywords

  • bone lesions
  • cytogenetic abnormalities
  • mutliple myeloma
  • myeloma-defining event
  • renal failure
  • translocations

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. / Greenberg, A. J.; Rajkumar, S Vincent; Therneau, Terry M; Singh, P. P.; Dispenzieri, Angela; Kumar, Shaji K.

In: Leukemia, Vol. 28, No. 2, 02.2014, p. 398-403.

Research output: Contribution to journalArticle

@article{c4b58b0c69a149c1b9001041f55e56e0,
title = "Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma",
abstract = "Multiple myeloma (MM) consists of several distinct cytogenetic subtypes, and we hypothesized that each subtype may have a unique mode of initial presentation and end-organ damage. We studied 484 patients with newly diagnosed MM to determine the relationship between specific myeloma-defining event (MDE) and the cytogenetic subtype. Patients were divided into four non-overlapping groups based on the MDE at diagnosis: isolated renal failure, isolated anemia, isolated lytic bone disease or a combination (mixed). MM with translocations without trisomies accounted for 30{\%} of all patients, but accounted for 50{\%} of patients with renal failure. Specifically, the t(14;16) translocation accounted for only 5{\%} of all MM patients, but was present in 13.5{\%} of patients with renal failure as MDE. Among patients with t(14;16), 25{\%} presented with renal failure only as MDE. Patients with isolated renal failure as MDE had significantly poorer survival compared with all other groups, whereas patients with bone disease as MDE had the best outcome (P<0.001). Our findings support the hypothesis that in addition to prognostic differences, there is significant heterogeneity in clinical presentation associated with the cytogenetic subtype, suggesting that MM encompasses a group of cytogenetically and phenotypically distinct disorders rather than a single entity.",
keywords = "bone lesions, cytogenetic abnormalities, mutliple myeloma, myeloma-defining event, renal failure, translocations",
author = "Greenberg, {A. J.} and Rajkumar, {S Vincent} and Therneau, {Terry M} and Singh, {P. P.} and Angela Dispenzieri and Kumar, {Shaji K}",
year = "2014",
month = "2",
doi = "10.1038/leu.2013.258",
language = "English (US)",
volume = "28",
pages = "398--403",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma

AU - Greenberg, A. J.

AU - Rajkumar, S Vincent

AU - Therneau, Terry M

AU - Singh, P. P.

AU - Dispenzieri, Angela

AU - Kumar, Shaji K

PY - 2014/2

Y1 - 2014/2

N2 - Multiple myeloma (MM) consists of several distinct cytogenetic subtypes, and we hypothesized that each subtype may have a unique mode of initial presentation and end-organ damage. We studied 484 patients with newly diagnosed MM to determine the relationship between specific myeloma-defining event (MDE) and the cytogenetic subtype. Patients were divided into four non-overlapping groups based on the MDE at diagnosis: isolated renal failure, isolated anemia, isolated lytic bone disease or a combination (mixed). MM with translocations without trisomies accounted for 30% of all patients, but accounted for 50% of patients with renal failure. Specifically, the t(14;16) translocation accounted for only 5% of all MM patients, but was present in 13.5% of patients with renal failure as MDE. Among patients with t(14;16), 25% presented with renal failure only as MDE. Patients with isolated renal failure as MDE had significantly poorer survival compared with all other groups, whereas patients with bone disease as MDE had the best outcome (P<0.001). Our findings support the hypothesis that in addition to prognostic differences, there is significant heterogeneity in clinical presentation associated with the cytogenetic subtype, suggesting that MM encompasses a group of cytogenetically and phenotypically distinct disorders rather than a single entity.

AB - Multiple myeloma (MM) consists of several distinct cytogenetic subtypes, and we hypothesized that each subtype may have a unique mode of initial presentation and end-organ damage. We studied 484 patients with newly diagnosed MM to determine the relationship between specific myeloma-defining event (MDE) and the cytogenetic subtype. Patients were divided into four non-overlapping groups based on the MDE at diagnosis: isolated renal failure, isolated anemia, isolated lytic bone disease or a combination (mixed). MM with translocations without trisomies accounted for 30% of all patients, but accounted for 50% of patients with renal failure. Specifically, the t(14;16) translocation accounted for only 5% of all MM patients, but was present in 13.5% of patients with renal failure as MDE. Among patients with t(14;16), 25% presented with renal failure only as MDE. Patients with isolated renal failure as MDE had significantly poorer survival compared with all other groups, whereas patients with bone disease as MDE had the best outcome (P<0.001). Our findings support the hypothesis that in addition to prognostic differences, there is significant heterogeneity in clinical presentation associated with the cytogenetic subtype, suggesting that MM encompasses a group of cytogenetically and phenotypically distinct disorders rather than a single entity.

KW - bone lesions

KW - cytogenetic abnormalities

KW - mutliple myeloma

KW - myeloma-defining event

KW - renal failure

KW - translocations

UR - http://www.scopus.com/inward/record.url?scp=84893790538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893790538&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.258

DO - 10.1038/leu.2013.258

M3 - Article

C2 - 24005246

AN - SCOPUS:84893790538

VL - 28

SP - 398

EP - 403

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -